New immunotherapy delays resistance to hormone therapy in prostate cancer
Innovative nanoparticles enhance immune response
Scientists at the Institute of Cancer Research (ICR) have developed a new form of immunotherapy that can delay resistance to hormone therapy and help men with prostate cancer.
The new treatment uses innovative nanoparticles to deliver a drug called olaparib directly to tumor cells. Olaparib is a type of PARP inhibitor that has been shown to be effective against cancers with a particular genetic mutation.
In a clinical trial, men with prostate cancer who received the new immunotherapy in addition to hormone therapy had a significantly longer time before their cancer became resistant to hormone therapy. The new treatment also helped to improve the body's immune response to the tumor.
The ICR team is hopeful that the new discovery will mean that olaparib can be given to more men with prostate cancer, and that it will help to improve their outcomes.
Comments